![]() We are thrilled to lead this round of financing," said Anand Mehra, M.D., General Partner of Sofinnova Ventures. The benefit provided by the RPE65 product candidate has the potential to be transformative for patients' lives. ![]() "The Spark team has significant experience across the core capabilities required to develop gene therapy products as evidenced by the quality of the company's pipeline and programs. Spark recently announced plans to open its corporate headquarters and manufacturing facility. "The funding will support the expansion of our team and ongoing development of our pipeline as we build the infrastructure needed for a first-in-class, FDA-approved gene therapy."įunds will be used to advance the company's deep pipeline of gene therapy programs including development of its lead Phase 3 program to address RPE65-related retinal dystrophies, as well as support the company's growth over the next three years. Marrazzo, co-founder and CEO of Spark Therapeutics. "With our combination of industry-leading gene therapy expertise, deep pipeline, and strong clinical results to-date, we've been able to attract a diverse set of blue-chip investors, giving us capital to maintain our position as a leader in the gene therapy field," said Jeffrey D. The Children's Hospital of Philadelphia (CHOP), a co-founder of the company, also participated significantly in the round. Rowe Price Associates, Inc., Wellington Management Company, LLP, and two undisclosed dedicated healthcare funds. Joining Sofinnova as new investors in the company are Brookside Capital, Deerfield Management Company, Rock Springs Capital, funds and accounts managed by T. PHILADELPHIA, /PRNewswire/ - Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of rare, debilitating diseases, today announced the successful completion of a $72.8 million Series B financing led by Sofinnova Ventures.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |